Natural Product-Inspired Method for Enhancing HIV Protease Inhibitors

增强 HIV 蛋白酶抑制剂的天然产物方法

基本信息

  • 批准号:
    8259867
  • 负责人:
  • 金额:
    $ 19.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-02-01 至 2014-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Highly active anti-retroviral therapy (HAART) has been remarkably effective for managing HIV infection / AIDS. However, patient compliance with HAART is often variable due to treatment- related complications. This is a serious problem that facilitates the emergence of drug resistance. One issue that contributes to HAART-associated complications is the poor metabolic stability and low cellular penetration of the HIV protease inhibitors. Our group has been exploring a new method for addressing these limitations. This strategy is directly inspired by the pharmacological properties of the natural product, FK506, which has a surprisingly long halftime in humans (t1/2 ~ 40 hrs) despite being an excellent substrate for P450 enzymes in vitro. We recently wondered whether this apparent contradiction might arise from this compound's high affinity for the FK506-binding protein (FKBP). Blood cells, including both erythrocytes and leukocytes, express unusually high levels of FKBP but they are virtually devoid of P450 enzymes. Therefore, we hypothesized that affinity-driven accumulation within this protected cellular niche might limit exposure to key metabolic enzymes and, thereby, extend drug lifetime. Moreover, FK506 is rapidly absorbed (~1 hr), highly penetrant to biological membranes and naturally targeted to leukocytes via its FKBP-binding moiety. Together, these properties appear to align with the major problems facing HIV protease inhibitors. Based on these observations, we tethered an FKBP-binding group to an amprenavir analog, creating a bifunctional molecule that can bind both FKBP and HIV protease. We found that the resulting compound retained anti-protease activity (IC50 ~ 20 nM). Moreover, it was now sequestered into blood cells (by at least 8-fold) and its half-life was increased by ~ 20-fold in mice. The lifetime of this compound was superior to that of ritonavir-boosted amprenavir and, moreover, its metabolic stability was now independent of ritonavir co-administration. Based on these promising initial findings, we now propose to carefully explore the molecular mechanisms governing this behavior. Specifically, we reason that cellular partitioning and lifetime are dictated, in part, by the affinity of the compound for FKBP. To explore this central hypothesis, we propose the following specific aims: (1) synthesize a collection of FKBP-binding amprenavir derivatives and measure their relative affinities for albumin, FKBP and HIV protease and (2) explore how cellular partitioning correlates with binding affinities and relative protein expression levels. From these observations, we expect to understand the key structure-activity relationships in the context of the ternary complex (i.e. FKBP-drug-HIV protease). The immediate goal of this study is to create potent, safe and long-lived HIV protease inhibitors that selectively target FKBP-expressing, HIV-infected cells. This study is significant because it addresses an important problem in the treatment of AIDS. The proposed work is innovative because it will explore a fundamentally new, "natural product-inspired" strategy. PUBLIC HEALTH RELEVANCE: HIV protease inhibitors are an important component of modern anti-retroviral strategies. However, these compounds have poor metabolic stability and low cellular penetration. Current solutions to these problems are effective, but they are also associated with significant complications, including nephrotoxicity. The goal of this project is to explore how a "natural product-inspired" strategy might directly improve the safety of HIV protease inhibitors and the treatment of AIDS.
描述(由申请人提供):高效抗逆转录病毒疗法(HAART)对管理HIV感染/ AIDS非常有效。然而,由于治疗相关的并发症,患者对HAART的依从性通常是可变的。这是一个严重的问题,促进了耐药性的出现。导致HAART相关并发症的一个问题是HIV蛋白酶抑制剂的代谢稳定性差和细胞渗透性低。我们的团队一直在探索解决这些限制的新方法。该策略直接受到天然产物FK 506的药理学性质的启发,FK 506在人体中具有令人惊讶的长半衰期(t1/2 ~ 40小时),尽管是体外P450酶的优良底物。我们最近想知道这种明显的矛盾是否可能源于这种化合物对FK 506结合蛋白(FKBP)的高亲和力。血细胞,包括红细胞和白细胞,表达异常高水平的FKBP,但它们实际上缺乏P450酶。因此,我们假设,在这种受保护的细胞生态位内的亲和力驱动的积累可能会限制关键代谢酶的暴露,从而延长药物寿命。此外,FK 506吸收迅速(约1小时),对生物膜具有高度渗透性,并通过其FKBP结合部分天然靶向白细胞。总之,这些特性似乎与HIV蛋白酶抑制剂面临的主要问题一致。基于这些观察结果,我们将FKBP结合基团与安普那韦类似物连接,产生了一种可以结合FKBP和HIV蛋白酶的双功能分子。我们发现所得化合物保留了抗蛋白酶活性(IC 50 ~ 20 nM)。此外,它现在被隔离到血细胞中(至少8倍),其半衰期在小鼠中增加了约20倍。这种化合物的寿命是上级的利托那韦加强安普那韦,而且,它的代谢稳定性现在是独立的利托那韦共同管理。基于这些有希望的初步发现,我们现在建议仔细探索控制这种行为的分子机制。具体地说,我们的理由是,细胞的分区和寿命,在一定程度上,由FKBP的化合物的亲和力。为了探索这一中心假设,我们提出了以下具体目标:(1)合成一系列FKBP结合安普那韦衍生物,并测量它们对白蛋白、FKBP和HIV蛋白酶的相对亲和力;(2)探索细胞分配如何与结合亲和力和相对蛋白质表达水平相关。从这些观察结果中,我们期望了解三元复合物(即FKBP-药物-HIV蛋白酶)背景下的关键结构-活性关系。这项研究的直接目标是创造有效,安全和长寿的HIV蛋白酶抑制剂,选择性靶向表达FKBP的HIV感染细胞。这项研究意义重大,因为它解决了艾滋病治疗中的一个重要问题。拟议的工作是创新的,因为它将探索一个全新的,“自然产品启发”的战略。 公共卫生相关性:HIV蛋白酶抑制剂是现代抗逆转录病毒策略的重要组成部分。然而,这些化合物具有差的代谢稳定性和低的细胞渗透性。目前对这些问题的解决方案是有效的,但它们也与严重的并发症有关,包括肾毒性。该项目的目标是探索“天然产物启发”策略如何直接改善HIV蛋白酶抑制剂的安全性和艾滋病的治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jason E Gestwicki其他文献

Exploration of the Binding Determinants of Protein Phosphatase 5 (PP5) Reveals a Chaperone-Independent Activation Mechanism.
蛋白磷酸酶 5 (PP5) 结合决定因素的探索揭示了一种不依赖分子伴侣的激活机制。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Shweta Devi;Annemarie Charvat;Zoe Millbern;Nelson Vinueza;Jason E Gestwicki
  • 通讯作者:
    Jason E Gestwicki

Jason E Gestwicki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jason E Gestwicki', 18)}}的其他基金

Adhesin Amyloid Biology
粘附素淀粉样蛋白生物学
  • 批准号:
    10726038
  • 财政年份:
    2023
  • 资助金额:
    $ 19.44万
  • 项目类别:
Chemical Biology Approaches to Studying Collagen IV Stability
研究胶原蛋白 IV 稳定性的化学生物学方法
  • 批准号:
    10723042
  • 财政年份:
    2023
  • 资助金额:
    $ 19.44万
  • 项目类别:
Research Training in Chemistry and Chemical Biology
化学和化学生物学研究培训
  • 批准号:
    10410908
  • 财政年份:
    2022
  • 资助金额:
    $ 19.44万
  • 项目类别:
Research Training in Chemistry and Chemical Biology
化学和化学生物学研究培训
  • 批准号:
    10624303
  • 财政年份:
    2022
  • 资助金额:
    $ 19.44万
  • 项目类别:
Differential Scanning Fluorimetry (DSF) Methods for Studying Protein Stability
研究蛋白质稳定性的差示扫描荧光 (DSF) 方法
  • 批准号:
    10626847
  • 财政年份:
    2021
  • 资助金额:
    $ 19.44万
  • 项目类别:
Differential Scanning Fluorimetry (DSF) Methods for Studying Protein Stability
研究蛋白质稳定性的差示扫描荧光 (DSF) 方法
  • 批准号:
    10462611
  • 财政年份:
    2021
  • 资助金额:
    $ 19.44万
  • 项目类别:
Differential Scanning Fluorimetry (DSF) Methods for Studying Protein Stability
研究蛋白质稳定性的差示扫描荧光 (DSF) 方法
  • 批准号:
    10184149
  • 财政年份:
    2021
  • 资助金额:
    $ 19.44万
  • 项目类别:
Activation of the 20S Proteasome to Normalize Tau Homeostasis
激活 20S 蛋白酶体使 Tau 稳态正常化
  • 批准号:
    9329344
  • 财政年份:
    2016
  • 资助金额:
    $ 19.44万
  • 项目类别:
Chemical Probes and Chaperone-Accelerated Turnover of Tau
化学探针和分子伴侣加速 Tau 蛋白的周转
  • 批准号:
    8519207
  • 财政年份:
    2012
  • 资助金额:
    $ 19.44万
  • 项目类别:
Natural Product-Inspired Method for Enhancing HIV Protease Inhibitors
增强 HIV 蛋白酶抑制剂的天然产物方法
  • 批准号:
    8416319
  • 财政年份:
    2012
  • 资助金额:
    $ 19.44万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 19.44万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 19.44万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 19.44万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 19.44万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 19.44万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 19.44万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 19.44万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 19.44万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 19.44万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 19.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了